HOME >> MEDICINE >> NEWS
Higher doses of cancer drug imatinib proven effective and safe

ortance as previous studies of another cancer drug (interferon alpha) have shown that CCR is associated with a 70 to 80 percent chance of 10-year survival, a positive prospect as the survival time for newly diagnosed CML patients is typically about five years.

Another measure of successful treatment is the number of patients with complete molecular response, occurring when the levels of BCR-ABL are so low that they are undetectable using a highly sensitive method called polymerase chain reaction. In past studies, patients who had undetectable levels of BCR-ABL after treatment have not relapsed after long-term follow up. In high-dose therapy patients, the incidence of complete molecular response was 28 percent compared to only seven percent of patients taking the standard dosage of imatinib.

"The high rates of complete cytogenetic and molecular response that we've seen in this study are unprecedented. If such responses have similar long-term significance as seen in previous studies, this translates into a major improvement in the prognosis of patients with CML," states Hagop Kantarjian, M.D., chairman of the Department of Leukemia at M. D. Anderson Cancer Center and the lead author of the study.

Researchers found that the high dosage of imatinib was generally well tolerated, with a similar rate of side effects as standard dose imatinib. To reduce more severe side effects, the dosage of imatinib was lowered to 600 mg or 400 mg daily for some patients, though a majority remained at the target dosage.

The disease did not transform beyond the chronic phrase in any of the study patients, and 98 percent had a complete hematologic response, meaning the number of white blood cells was no longer out of control and the signs and symptoms of leukemia were gone.

The results of the study indicate that patients in the early stage of this cancer may benefit from higher doses of the drug imatinib in their initial treatment to safely and effe
'"/>

Contact: Aislinn Raedy
araedy@hematology.org
202-776-0544
American Society of Hematology
1-Apr-2004


Page: 1 2 3

Related medicine news :

1. Higher folate intake associated with decreased risk of hypertension in women
2. Higher incidence of rejection following early steroid withdrawal
3. Higher radiation doses help some lung cancer patients live longer
4. Higher dose of Gleevec leads to increased remission in CML patients
5. Higher education or larger brain size may protect against dementia later in life, new study finds
6. Higher cost sharing reduces plans drug expenditures, but boosts enrollee costs
7. Higher nocturnal blood pressure predictive of kidney disease in diabetes
8. First quarter 2002 prescription drug spending: Higher again, but rate of increase drops
9. Higher rate of improvement, lower rate of adverse effects with clarithromycin for acute exacerbations of chronic bronchitis
10. Cancer Rates In Children Of Nuclear Industry Employees No Higher Than General Population In England And Wales
11. New Study Finds Blacks Face 38 Percent Higher Stroke Risk

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Higher doses cancer drug imatinib proven effective and safe

(Date:10/30/2014)... 2014 Timothy, InstaKNOT’s 4-year-old ... firefighters, showing that you are never too young to ... firefighters Tracey and Carl at the 2013 Santa Arriving ... Pompano Beach Chamber of Commerce. Tracey gave Timothy a ... Timothy wear his real fireman’s hat, and extending an ...
(Date:10/30/2014)... 2014 Don Allred Insurance, a leading ... plans for North Carolina residents, is excited to announce ... Holly Hill Mall. The new branch has been up ... customers through all facets of the insurance selection process ... spokesman Scott Allred couldn’t be happier with the timing ...
(Date:10/30/2014)... Portland, OR (PRWEB) October 30, 2014 ... law firm Hodgkinson Street LLC announces new branding ... Hodgkinson Street Mepham . After David Mepham’s promotion ... revitalizes their brand and website to include Mepham’s name ... leading medical malpractice and mediation firm, the decision to ...
(Date:10/30/2014)... 2014 Paramount Rx, a full-service prescription ... efforts to help people save money through its innovative ... for prescription drugs in the new health care system, ... to bridge the relationship between consumers, businesses and the ... challenges people face today with medical costs is the ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. ... with prostate cancer who also have certain heart problems may ... new study suggests. , , The therapy in question is called ... reduce levels of male hormones to prevent the growth of ... research, this hormone therapy was linked to triple the risk ...
Breaking Medicine News(10 mins):Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3
(Date:10/30/2014)... FRANCISCO , Oct. 30, 2014  Nektar Therapeutics ... results for the third quarter ended September 30, 2014 ... U.S.-based financial markets. Howard Robin , president and ... review the results beginning at 5:00 p.m. Eastern Time ... press release and a live audio-only Webcast of the ...
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation ... and development company specializing in oncology, today announced ... its lead drug candidate, aldoxorubicin.  The presentation, titled, ... Approach," will be given by Sant P. ... Oncology Center and principal investigator of the Company,s ...
(Date:10/30/2014)... -- , Extensively hydrolyzed milk formula with LGG ... Cow milk protein allergy (CMPA) is the leading cause of food ... has been managed by eliminating milk proteins from a ... is possible to help build of oral tolerance to ... the first year of life by using an extensively ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
Cached News: